CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.

Abstract

CHR-2797 is a novel metalloenzyme inhibitor that is converted into a pharmacologically active acid product (CHR-79888) inside cells. CHR-79888 is a potent inhibitor of a number of intracellular aminopeptidases, including leucine aminopeptidase. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines in vitro and in vivo and shows selectivity for transformed over nontransformed cells. Its antiproliferative effects are at least 300 times more potent than the prototypical aminopeptidase inhibitor, bestatin. However, the mechanism by which inhibition of these enzymes leads to proliferative changes is not understood. Gene expression microarrays were used to profile changes in mRNA expression levels in the human promyelocytic leukemia cell line HL-60 treated with CHR-2797. This analysis showed that CHR-2797 treatment induced a transcriptional response indicative of amino acid depletion, the amino acid deprivation response, which involves up-regulation of amino acid synthetic genes, transporters, and tRNA synthetases. These changes were confirmed in other leukemic cell lines sensitive to the antiproliferative effects of CHR-2797. Furthermore, CHR-2797 treatment inhibited phosphorylation of mTOR substrates and reduced protein synthesis in HL-60 cells, both also indicative of amino acid depletion. Treatment with CHR-2797 led to an increase in the concentration of intracellular small peptides, the substrates of aminopeptidases. It is suggested that aminopeptidase inhibitors, such as CHR-2797 and bestatin, deplete sensitive tumor cells of amino acids by blocking protein recycling, and this generates an antiproliferative effect. CHR-2797 is orally bioavailable and currently undergoing phase II clinical investigation in the treatment of myeloid leukemia.

DOI: 10.1158/0008-5472.CAN-07-6627

6 Figures and Tables

050200920102011201220132014201520162017
Citations per Year

198 Citations

Semantic Scholar estimates that this publication has 198 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Krige2008CHR2797AA, title={CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.}, author={David G. Krige and Lindsey A Needham and Lindsay J Bawden and Nicol{\'a}s Flores and Hannah Farmer and Lauren E C Miles and Erica Stone and Juliana Callaghan and Stephen Chandler and Vanessa Clark and Patricia Kirwin-Jones and Val{\'e}rie Legris and Jo Owen and Thakor R. Patel and Steve Wood and Gary M. Box and David Laber and Rajesh Odedra and Annette Wright and Laurence M. Wood and Suzanne A. Eccles and Elisabeth A Bone and Andrew P Ayscough and Alan H. Drummond}, journal={Cancer research}, year={2008}, volume={68 16}, pages={6669-79} }